However, in a recent paper, several cases of very elderly patients with EBV-related LPD in the absence of immunodeficiency were presented. 5 In our patients of different age groups, no immunodeficiency could be detected. The three presented cases indicate that EBV-related LPDs occur more frequently than currently recognized. We suggest that in all cases of B-cell lymphomas with unusual histological features reminiscent of post-transplant lymphoproliferative disorders, an EBER in situ hybridization should be performed. Analogous to the post-transplant lymphoproliferative disorders, the diagnosis of EBV-related LPD may have important therapeutic consequences. Further studies are required to identify the surplus value of cytotoxic chemotherapy in combination with anti-CD20 antibodies. Strikingly, two patients suffered from autoimmune phenomena. It is unclear whether this occurred by chance or whether this forms a clue to the etiology of these lymphomas. In conclusion, the three presented cases demonstrate that EBV-related B-cell lymphomas can occur in both young and old patients without detectable underlying immunodeficiency. 
TO THE EDITOR
Matched unrelated donors (MUD) and haploidentical relatives are alternative sources of hematopoietic stem cells for patients with hematological malignancies without a suitable human leukocyte antigen (HLA)-compatible related donor. Those transplants, however, are associated with increased incidence of graft rejection and failure. 1, 2 A second hematopoietic stem cell transplant (HSCT) may be necessary in these circumstances. 3 In cases where the original donor is not available or in whom autologous hematopoietic stem cells could not be collected prior to the transplant, cord blood may provide a rapidly available source of hematopoietic progenitor cells. 4 However, long-term complications following cord blood transplant in this setting are largely unknown. Here we describe two patients who received unrelated umbilical cord blood (UCB) stem cell transplants as salvage therapy after rejection of the first HSCT.
Case report #1
A 38-year-old patient with chronic myeloid leukemia (CML) in blastic crisis underwent a haploidentical sibling peripheral blood stem cell transplant. The conditioning regimen included cyclophosphamide 60 mg/kg Â 2 days, thiotepa 5 mg/kg Â 1 day, total body irradiation (TBI) 300cGy Â 4 days and antithymocyte globulin (ATG) 15 mg/kg Â 2days.
Despite initial complete cytogenetic and hematologic remission and recovery of an absolute neutrophil count (ANC) of 0.5 Â 10 9 /l and platelet count of 420 Â 10 9 /l on days þ 10 and þ 12, the patient developed secondary graft rejection at day þ 20, with an ANC of 0.2 Â 10 9 /l and a platelet count of 7 Â 10 9 /l. The rejection occurred following a preparative regimen considered to be fully ablative and immunosuppressive. We thus elected to proceed with a one antigen-mismatched UCB transplant (containing a total nucleated cell dose of 3.7 Â 10 7 /kg). Preparative regimen for the second transplant consisted of fludarabine 25 mg/m 2 days À5 to À1, and ATG 20 mg/kg days À3 to À1. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus alone, dosed to deliver a target through a concentration of 5-15 ng/ml. The time interval between the two transplants was 6 weeks.
After UCB transplant, the patient achieved an absolute neutrophil count of 500/ml and platelet count of 20 000/ml on days þ 41 and þ 92, respectively, and engraftment was maintained through the remainder of the patient's life. PCRbased DNA microsatellite polymorphism analysis revealed complete donor chimerism on transplant day þ 27. The posttransplant course was complicated by recurrent infections including CMV viremia, coagulase negative staphylococcus infection and herpes zoster. Other complications included grade 3 hemorrhagic cystitis and biopsy-proven stage 3 acute GVHD of the skin, which responded to i.v. methyl prednisolone. Chronic GVHD of the liver was diagnosed 10 months posttransplant, and responded to tacrolimus, methylprednisolone, infliximab and rapamycin. At 14 months post-transplant, the patient developed acute onset of left-sided weakness and urinary incontinence. Magnetic resonance scan showed extensive subcortical white matter disease. Brain biopsy revealed progressive multifocal leukoencephalopathy (PML) and JC virus (JCV). There was a minimal response to cidofovir and withdrawal of immunosuppression. Clinical course was marked by a slight improvement of the left-sided paresis, but approximately 1 month before death, there was rapid worsening of motor function and dementia. At 2 years post-transplant while in complete remission from his CML, the patient developed acute pneumonia and septic shock and died. Autopsy confirmed acute lobar pneumonia with multifocal abscess formation involving both lungs. Microorganism aggregates were consistent with staphylococcus aureus and enterococci. JC virus was found mainly in the astrocyte nuclei in the left superior gyrus and in the right frontal cortex.
Case report #2
A 29-year-old male with acute myeloid leukemia (AML) in the first relapse after a short first CR of 6 months duration received a HSCT from a MUD. The conditioning regimen consisted of fludarabine 30 mg/m 2 , i.v. busulfan 0.8 mg/kg on days À5 to À2, and ATG 10 mg/kg on days À4 to À1. GVHD prophylaxis consisted of tacrolimus and methotrexate 5 mg/m 2 on days þ 1, þ 3, þ 6 and þ 11. Neutrophil and platelet engraftment occurred on days þ 13 and þ 10, respectively.
Secondary graft failure and leukemia relapse occurred 31 days post-transplant. The donor was not available, so we elected to proceed with a three antigen-mismatched UCB transplant (containing a total nucleated cell dose of 2.3 Â 10 7 /kg). The conditioning regimen included fludarabine 25 mg/m 2 on days À5 to À2, melphalan140 mg/m 2 on days À3 and À2 and rabbit ATG 2 mg/kg on days À3 to À1. UCB transplantation took place 10 weeks after the first transplant.
The patient achieved an absolute neutrophil count (ANC) 40.5 Â 10 9 /l and platelets 420 Â 10 9 /l on days 25 and 39 post-UCB transplant, respectively. Platelet and neutrophil counts were maintained above this threshold throughout the remaining clinical course. Peripheral blood DNA microsatellite polymorphism analysis on day þ 30 showed 100% donor chimerism.
The patient's early UCB post-transplant course was complicated by hemorrhagic cystitis associated with polyomavirus, itraconazole-related liver toxicity and alpha hemolytic streptococcus bacteremia. No GVHD was observed. At 3 months posttransplant, the patient experienced high fever, night sweats, weight loss and generalized lymphadenopathy. Computerized tomography and gallium scans showed lymphomatous lesions in the left axilla, bilateral submandibular regions, left neck, right hilum and left paratracheal regions. Cervical lymph node biopsy showed Ebstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder, polymorphous type, CD20 positive. There was no response to tapering of immune suppression, palliative radiotherapy to the neck and mediastinum and rituximab 1 g/m 2 . He developed adenovirus infection of the lung and fungal pneumonia, leading to respiratory failure, diffuse alveolar hemorrhage and, subsequently, multiorgan failure. Death occurred 6 months post-cord blood transplant. Autopsy showed torulopsis glabrata sepsis.
Discussion
The second HSCT may be life saving for patients failing to engraft or rejecting their graft after a myeloablative conditioning regimen. 3 Prompt availability of donor cells is a key part of the management. While this is usually not possible with unrelated donors (and occasionally related donors), UCB products are rapidly available for most patients as there is reduced stringency for product selection based upon HLA type, and the UCB HLA typing is done at the time of storage.
In this report, we describe two adults who had graft rejection following haploidentical and MUD HSCT, who achieved donor neutrophil and platelet recovery with UCB transplants. Both patients achieved complete remissions of their hematological malignancies. However, both died, 6 months and 2 years post-UCB transplant, from multiple complications related to delayed immune recovery. Both patients received a second preparative regimen (fludarabine, ATG, 7melphalan), intended to produce further recipient immunosuppression and improve the likelihood of engraftment of the UCB.
Early transplant-related mortality after second allogenic HSCT for graft failure may be as high as 50-60%, mainly related to infections, GVHD and veno-occlusive disease of the liver. 5 It has been reported that an HLA-identical sibling donor, duration of time between transplants of greater than 80 days, GVHD prophylaxis with cyclosporin for the second transplant and a CMV serologically negative recipient may be associated with favorable outcome. 5 One of our patients developed PML associated with JCV infection 14 months post-UCBT. PML is a fatal demyelinating disease of the central nervous system that predominantly affects immunocompromised individuals. The etiologic agent JCV is a widespread polyomavirus targeting specifically the myelinproducing oligodendrocytes of the brain. During periods of immune suppression, the virus can be reactivated from the lymphoid tissues and kidney, causing targeted myelin destruction and corresponding neurological deficits. It has been reported rarely in bone marrow transplant recipients. 6, 7 The other patient developed EBV-related PTLD. Interestingly, the occurrence of this complication does not appear to be increased after UCB transplant. Barker et al described a cumulative incidence of EBV-PTLD of 2% at 2 years in a cohort of 277 patients receiving UCB transplant. The incidence was similar to that seen after allogenic HSCT from other sources. 8 The fatal infectious complications experienced by both of our patients emphasize the importance of recovery of immune function following UCB transplantation. In the patients reported here, immune deficits may have been exacerbated by the previous transplantations or the second preparative regimen. The severity of infectious complications experienced by these patients suggests that additional treatments may be required to reduce the infection risk in similarly treated patients in the future. Finally, omission of the pre-UCB transplant preparative regimen or reducing its intensity could be considered, but might risk UCB engraftment. In spite of these immune complications, the re-establishment of neutrophil and platelet engraftment in both patients suggests that the 'rescue' use of UCB, as described here, could be explored further. The marked improvement in the survival of children treated for cancer has focused increased attention on the long-term sequellae associated with contemporary intensive therapies. Second malignancies have been reported in patients treated for variety of childhood cancers, and have been associated with alkylating agents, topoisomerase inhibitors and radiation. Genetic differences in drug metabolizing enzymes may explain some of the variability in drug response. 1 Thus, common genetic polymorphisms in drug metabolizing enzymes may result in impaired detoxification of chemotherapeutic agents, resulting in higher levels of genotoxic substrates that could contribute to increased DNA damage and subsequent development of second neoplasms.
Glutathione S-transferases (GST) are supergene family capable of detoxifying genotoxic electrophilic compounds by catalyzing their conjugation to glutathione. At least five of the human GST genes have functional polymorphisms. 2 The GSTM1 and GSTT1 polymorphisms are deletions, with homozygous variant patients producing no active protein. The GSTM1 gene is homozygously deleted in 50% of Caucasian individuals and GSTT1 in 20%.
3 GSTP1 gene is also polymorphic, with a codon 105 isoleucine-valine substitution (GSTP n 1B), resulting in altered catalytic activity and thermal stability of the enzyme. The GSTM1 and GSTT1 alleles have been associated with increased risk of development of a variety of solid tumors and leukemia. 4 The risk for cancer conferred to individuals who carry homozygous deletions in GSTM1 and GSTT1 appears to be small in magnitude; however, the magnitude of risk is larger when interactions with other carcinogenic factors such as smoking are considered. 4 Epipodophyllotoxins, anthracyclines and cyclophosphamide are also inactivated by these enzymes, play integral roles in the treatment of pediatric leukemias, and are also risk factors for the development of secondary leukemias.
We sought to evaluate the role that GST genotypes play in modifying the risk of secondary malignancies in children treated for acute leukemia. We compared the proportion of GSTM1, GSTT1 and GSTP n 1B genotypes in pediatric patients who developed secondary cancers after treatment of acute leukemia to a control group of pediatric patients who did not develop a secondary malignancy while treated on identical protocols. A total of 449 patients under 16 years of age were treated between 1 January 1961 and 12 October 2000 for acute leukemia and were registered in Cancer Registry of Slovenia. Of these, 16
